Advancing in Acute Promyelocytic Leukemia Therapy Research: The Role of 3-Alkylpyridine Alkaloid Analogs in Overcoming Genetic and Molecular Barriers.

INTRODUCTION

Acute leukemias are malignant clonal disorders of blood cells, originating in the bone marrow. Acute Promyelocytic Leukemia (APL), when left untreated, progresses unfavorably, often resulting in severe hemorrhaging. Chemotherapy remains a key therapeutic strategy; however, the need for discovering new antitumor agents is critical. This study aims to evaluate the cytotoxic effects of 16 synthetic analogs of 3-alkylpyridine alkaloids (3-APA) on various APL cell lines and Peripheral Blood Mononuclear Cells (PBMCs), with the goal of identifying promising new therapeutic candidates for APL treatment.

MATERIALS AND

METHODS

The cytotoxic effects of 16 synthetic 3-APA analogs were assessed on APL cell lines (NB4, NB4-LR2, and HL-60) and PBMC. The MTT assay was used to evaluate the cytotoxic profiles of the compounds. Apoptosis induction and cell cycle arrest were analyzed using flow cytometry. Gene expression changes related to apoptosis (TP53, p21, BAK, Bcl-2, AKT) and oxidative stress (NOX-1, NOX-2, NOX-4, P47-phox) were measured through RT-qPCR. Additionally, chemical similarity analysis via ChEMBL was performed to predict potential molecular targets, including ROS1 and PARP1.

RESULTS

The results demonstrated distinct cytotoxic responses among the tested cell lines. All 16 compounds induced apoptosis in the APL cell lines, leading to a notable decrease in the expression of antiapoptotic genes, including p21, Bcl-2, and AKT, which contributed to cell death. Gene expression analysis revealed an increase in oxidative stress markers, particularly NOX-2 and p47-phox in the NB4 cell line, and NOX-1 and NOX-4 in the NB4-LR2 lineage, suggesting potential mechanisms of cellular damage and resistance.

DISCUSSION: The 3-APA analogs showed significant cytotoxic effects against APL cell lines, with distinct selectivity profiles. The induction of apoptosis and the downregulation of anti-apoptotic genes underscore the potential of these compounds as promising therapeutic agents. The observed changes in oxidative stress gene expression further suggest a mechanism of action involving oxidative damage, which could contribute to the efficacy of the compounds, especially in overcoming resistance in the ATRA-resistant NB4-LR2 cell line. Additionally, the prediction of ROS1 and PARP1 as potential molecular targets opens new avenues for further investigation.

CONCLUSION

This study highlights the potential of 3-APA analogs as effective cytotoxic agents in the treatment of APL. The compounds demonstrated significant apoptotic activity and altered gene expression, particularly in apoptosis regulation and oxidative stress pathways. These findings suggest that 3-APA analogs may serve as valuable candidates for future therapeutic development in APL treatment, warranting further research into their molecular mechanisms and clinical applicability.